List of Acuvail drug patents
Acuvail is owned by Allergan.
Acuvail contains Ketorolac Tromethamine.
Acuvail has a total of 4 drug patents out of which 0 drug patents have expired.
Acuvail was authorised for market use on 22 July, 2009.
Acuvail is available in solution/drops;ophthalmic dosage forms.
The generics of Acuvail are possible to be released after 15 August, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7842714 | ALLERGAN | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(1 year, 5 months from now) | |
| US8512717 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(5 years from now) | |
| US9192571 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(5 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACUVAIL family patents
30
United States
6
European Union
5
Australia
5
Spain
4
Poland
4
Japan
4
Canada
3
China
3
Denmark
2
Austria
2
Korea, Republic of
2
Brazil
2
New Zealand
1
Hong Kong
1
Malaysia
1
Ukraine
1
Germany
1
Israel
1
Mexico
1
Slovenia
1
Hungary
1
South Africa
1
Colombia
1
Russia
1
Croatia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic